BioNTech SE (BNTX) Announces 5M Share Proposed Public Offerings of ADSs and Rights Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioNTech SE (BNTX) files to offer 5 Million ADSs and 750K for selling shareholders
July 21, 2020 8:27 AM EDTBioNTech SE (NASDAQ: BNTX) files to offer 5 Million ADSs and 750K for selling shareholders.
From the filing:
We are offering 5,000,000 American Depositary Shares,... More
BofA Securities Upgrades BioNTech (BNTX) to Buy as Positive Vaccine Updates Likely to Continue
July 21, 2020 4:19 AM EDT(Updated - July 21, 2020 6:53 AM EDT)
(updated to add analyst comments)
BofA Securities analyst Tazeen Ahmad upgraded BioNTech (NASDAQ: BNTX) from Neutral to Buy with a price target of $105 (from $71), saying the company's vaccine program with Pfizer is starting to differentiate... More
Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
July 20, 2020 8:46 AM EDTBioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are... More
